Brean Murray Starts Poniard Pharmaceuticals (PARD) with a Buy
More News related to PARD
- Poniard Pharmaceuticals to Present Updated Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and Final Phase 1 Cardiac Safety Trial Results
- Poniard Pharma (PARD) option volume and prices elevated into data
- Active equity option families in first 30 minutes of trading: BAC C GE PARD
- Poniard Pharma (PARD) Posts Q3 Loss of $0.29, In-Line with Estimates
- Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
More News related to New Coverage
- ImmunoGen (IMGN) to Make Several Poster Presentations as AACR-NCI-EORTC Conference
- BofA's Ken Lewis Sees Crisis 'Abating', But Says Banking Has 'Some Way to Go' to Recover
- Novavax (NVAX) Begins Phase IIa of Flu VLP Vaccine Candidate in Adults 60 and Over
- Catalyst Pharma (CPRX) Receives $1.2M Grant from U.S. DoD for Study of Vigabatrin
- TASER Int. (TASR) Announces U.S. Army Ordered 2500 Taser X26 ECDs
Brean Murray initiates coverage on Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) with a Buy rating and $11 price target.
The price target is derived by applying a 30 multiple and 35% discount rate to our 2013 EPS projection of $1.03, which assumes a 2H10 launch of picoplatin in second-line SCLC and a 3Q11 launch of picoplatin in first-line metastatic CRC. Brean Murray believes that these two markets add up to $5 billion worldwide, of which they assume almost $1.2 billion in sales in 2013.
The firm said, "We believe that the Phase 2 data to date in multiple indications, combined with our expectations for positive Phase 3 SCLC trial results in 2H09, will drive a partnership yielding global double-digit royalties, as well as a commitment from the partner to fully fund development of picoplatin in metastatic CRC, and potentially in CRPC and ovarian cancer. We expect a late 2009 NDA submission followed by a mid-2010 approval in the U.S. Picoplatin has the potential to become the preferred treatment for second-line SCLC, given topotecan's limited efficacy in platinum-resistant and highly refractory patients and no other approved competition in the setting"
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
